Background: ETC-159 is a small molecule selectively inhibiting the O-acyltransferase PORCN (porcupine) that is required for the palmitoylation of all Wnts. Preclinical studies show anti-tumour effects when administered orally using different dosing schedules. In this first-in-human study we investigate safety, tolerability, maximum tolerated dose (MTD), pharmacokinetic (PK) and pharmacodynamic (PD) of ETC-159 in patients (pts) with advanced or metastatic solid tumours.